The Top 5 Biosimilars Articles for the Week of February 24

The Center for Biosimilars® recaps the top stories for the week of February 24, 2020.
February 28, 2020


Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of February 24, 2020.

Number 5: A new review analyzing the risk of cancer in patients with psoriasis found no increased risk for those treated with biologics. 

Number 4: The FDA amends the definition of “biological product” in its final rule regarding the regulatory shift that begins March 23, when insulin and other biological products shift to a different approval pathway. 

Number 3: A year-in-review article outlines 2019 studies about nonmedical switching and finds evidence to support moving from originator biologics to biosimilars in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.

Number 2: AbbVie reports strong revenues for next-generation products the company hopes will provide fill-in revenue as Humira sales decline and more adalimumab biosimilars to the blockbuster arthritis drug enter international markets.

Number 1: The launch of Pfizer’s trastuzumab biosimilar, Trazimera, means the originator product Herceptin now has 3 biosimilar competitors.


To read all of these articles and more, visit centerforbiosimilars.com.
 

x-button

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.